Related references
Note: Only part of the references are listed.124I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma
Mariam S. Aboian et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
First Experience Using 18F-Flubrobenguane PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma
Lukas Kessler et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman et al.
LANCET (2021)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Nuclear medicine and molecular imaging advances in the 21st century
Sofia C. Vaz et al.
BRITISH JOURNAL OF RADIOLOGY (2020)
Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis
Sangwon Han et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer
Manuel Weber et al.
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
Daniel A. Pryma et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities
Marcus Ruhlmann et al.
NUCLEAR MEDICINE COMMUNICATIONS (2018)
123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel
V. Lewington et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
Grace Kong et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
Donika Plyku et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
A phantom study: Should 124I-mIBG PET/CT replace 123I-mIBG SPECT/CT?
Casper Beijst et al.
MEDICAL PHYSICS (2017)
Quantitative Comparison of 124I PET/CT and 131I SPECT/CT Detectability
Casper Beijst et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)
Ameya D. Puranik et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I
Walter Jentzen et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Patient-Specific Dosimetry Using Pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) Dynamic PET/CT Imaging Before [131I]mIBG Targeted Radionuclide Therapy for Neuroblastoma
Shih-ying Huang et al.
MOLECULAR IMAGING AND BIOLOGY (2015)
A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma
Alexander Kroiss et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT
A. Kroiss et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies
Verena Hartung-Knemeyer et al.
ANNALS OF NUCLEAR MEDICINE (2012)
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL)
S. Zovato et al.
HORMONE AND METABOLIC RESEARCH (2012)
High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
Michael S. Hofman et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2012)
Tumor Dosimetry Using [124I]m-iodobenzylguanidine MicroPET/CT for [131I]m-iodobenzylguanidine Treatment of Neuroblastoma in a Murine Xenograft Model
Youngho Seo et al.
MOLECULAR IMAGING AND BIOLOGY (2012)
Is there still a role for SPECT-CT in oncology in the PET-CT era?
Rodney J. Hicks et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer
George Sgouros et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Efficacy of Dosimetric Versus Empiric Prescribed Activity of 131I for Therapy of Differentiated Thyroid Cancer
Joanna Klubo-Gwiezdzinska et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Radioiodinated Metaiodobenzylguanidine (MIBG): Radiochemistry, Biology, and Pharmacology
Shankar Vallabhajosula et al.
SEMINARS IN NUCLEAR MEDICINE (2011)
Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET
Chang-Lae Lee et al.
MEDICAL PHYSICS (2010)
Usefulness of I-123-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial
Gregory A. Wiseman et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer
Walter Jentzen et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Share Paper
